Additional funding opportunities
Research Funding Opportunities
Grants Awarded for Health Sciences Research
| Title | Type | $ Amount | Activity | Investigator |
Unit |
Sponsor | Date |
|---|---|---|---|---|---|---|---|
| Prescribing Vitamin D: An Exploratory Comparative Survey of University of Arizona Integrative Medicine Fellows' Attitudes and Practices | Contract | $101,919.00 | Research | Lisa Alschuler | Andrew Weil Ctr Intgrtv Med | Pharmavite | 01/2020 |
| Validation of Spinal Neurotensin Receptor 2 as an Analgesic Target | Grant | $1,539,731.00 | Research | Amol Patwardhan | Anesthesiology | National Institute of Neurological Disorders and Stroke | 10/2020 |
| Technical Study: Analytical Performance Evaluation of Cobas Plus | Contract | $553,527.00 | Clinical Trial | Ryan Matika | Anesthesiology | Roche Diagnostics Operations, Inc. | 10/2020 |
| Coronavirus Telehealth Resource Centers | Grant | $828,571.00 | Other Sponsored Activity | Ronald Weinstein | Arizona Telemedicine Program | Health Resources and Services Administration | 06/2020 |
| A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 with Placebo and with Tofacitinib in Combination with Conventional Synthetic DMARDs.... | Contract | $314,050.00 | Clinical Trial | Chian Kwoh | Arthritis Center-Research | IQVIA RDS Inc. | 03/2020 |
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients with Diffuse Cutaneous Systemic Sclerosis or Systemic Sclerosis-Associated... | Contract | $55,928.00 | Clinical Trial | Chian Kwoh | Arthritis Center-Research | Cumberland Pharmaceuticals, Incorporated | 07/2020 |
| Early Origins of Chronic Lung Disease: Outcomes into the Fifth Decade of Life | Grant | $6,030,330.00 | Research | Fernando Martinez | Asthma/Airway Disease Rsch Ctr | National Heart, Lung, and Blood Institute | 04/2020 |
| AZithromycin Therapy in Preschoolers with a Severe Wheezing Episode Diagnosed at the Emergency Department (AZ-SWED) | Cooperative Agreement | $1,466,425.00 | Research | Fernando Martinez | Asthma/Airway Disease Rsch Ctr | National Heart, Lung, and Blood Institute | 09/2020 |
| Beyond Pseudotime: Enhanced Single-cell GEnomics Tools for Understanding the Temporal Dynamics of Development and Disease | Grant | $1,822,950.00 | Research | Darren Cusanovich | Asthma/Airway Disease Rsch Ctr | National Institute of General Medical Sciences | 08/2020 |
| Binational Early Asthma & Microbiome Study (BEAMS) | Grant | $15,309,471.00 | Research | Fernando Martinez | Asthma/Airway Disease Rsch Ctr | National Institute of Allergy and Infectious Disease | 08/2020 |
| Epitope Open-Label Extension Study to Evaluate the Long-Term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children (EPOPEX) | Contract | $173,290.72 | Clinical Trial | Heather Cassell | Asthma/Airway Disease Rsch Ctr | Pharmaceutical Research Associates | 02/2020 |
| Development of Surfactant Protein A-derived Peptidomimetics for the Treatment of Asthma | Grant | $86,381.00 | Research | Scott Boitano | Asthma/Airway Disease Rsch Ctr | RaeSedo, LLC | 09/2020 |
| Octapharma's Octagam 10% Gam10-09 Study | Contract | $64,944.00 | Research | Michael Daines | Asthma/Airway Disease Rsch Ctr | Octapharma Pharmazeutika Produktionsgesellschaft mbH (Austria) | 08/2020 |
| A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses.... | Contract | $273,767.50 | Clinical Trial | Cori Daines | Asthma/Airway Disease Rsch Ctr | Janssen Research & Development, LLC | 01/2020 |
| Immunometabolic Phenotypes in Adult Severe Asthma and Disease Progression | Cooperative Agreement | $339,110.00 | Research | Deborah Meyers | Asthma/Airway Disease Rsch Ctr | Brigham and Women's Hospital | 09/2020 |
| B Cell-Adaptive Immune Profile in Emphysema-Predominant COPD | Grant | $3,364,046.00 | Research | Francesca Polverino | Asthma/Airway Disease Rsch Ctr | National Heart, Lung, and Blood Institute | 07/2020 |
| Area Health Education Centers Program COVID | Grant | $95,455.00 | Instruction | Daniel Derksen | AZ Health Education Centers | Health Resources and Services Administration | 06/2020 |
| A Phase II Trial of PET-Directed Therapy using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, with or without Brentuximab Vedotin Plus Nivolumab, Foll | Contract | $40,100.00 | Clinical Trial | Abhijeet Kumar | Cancer Center Division | Mayo Foundation for Medical Education and Research (Mayo Clinic) | 06/2020 |
| A Phase I/II Pilot Trial, Single Arm, Open Label, of Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined with Tumor Treatment Fields (TTF) in Patient with Metastatic Pancreatic... | Contract | $161,422.69 | Clinical Trial | Hani Babiker | Cancer Center Division | NovoCure | 09/2020 |
| Evaluation of Reglagene Compounds in Cancer Cell Lines with DNA Damage Mutations | Contract | $2,000.00 | Research | Joann Sweasy | Cancer Center Division | Reglagene, LLC | 10/2020 |
| Imagestream-X MKII to Enhance Cell Biology Research | Grant | $596,093.00 | Research | Deepta Bhattacharya | Cancer Center Division | National Institutes of Health | 07/2020 |
| A Phase 1/2 Study of ZN-c3 as a Single Agent in Combination with Talazoparib or Pembrolizumab in Patients with Solid Tumors | Contract | $138,409.52 | Clinical Trial | Pavani Chalasani | Cancer Center Division | K-Group Beta, Inc. | 03/2020 |
| A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab | Contract | $208,612.70 | Clinical Trial | Gregory Woodhead | Cancer Center Division | Astrazeneca | 06/2020 |
| A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-cell Lymphoma (PTCL) in Adults Age 60 and Above | Contract | $147,691.00 | Clinical Trial | Daniel Persky | Cancer Center Division | Seattle Genetics, Incorporated | 05/2020 |
| A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Locally Advanced/Metastatic or Surgically Unresectable.. | Contract | $171,440.00 | Clinical Trial | Aaron Scott | Cancer Center Division | Incyte Corporation | 05/2020 |